Log In
Print
BCIQ
Print
Print this Print this
 

Keytruda, pembrolizumab (MK-3475) (formerly lambrolizumab)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHumanized IgG4 mAb against programmed cell death 1 (PDCD1; PD-1; CD279)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

15

$4.0M

$4.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today